SOLD
Hilco is seeking offers to acquire the intellectual property and tangible assets of CellulaREvolution Limited (In Administration) (“CellRev” or the “Company”) on behalf of the Joint Administrators of the Company, Ed Connell and Mike Kienlen of Armstrong Watson LLP.
Founded in 2019 as a Newcastle University spin-out, CellRev rapidly positioned itself at the forefront of continuous bio-processing innovation for adherent cell cultures. Leveraging proprietary enzyme technology and process know how, the Company developed solutions designed to enable cost-effective and scalable cell culture for cell-based vaccine, therapy and drug developers, with a focus on high-value markets including cultivated meat, regenerative medicine, vaccines, and advanced biologics.
CellRev’s flagship product, AggreGuard, is a specialist enzyme blend designed to stop cells from clumping together during the manufacturing process. By keeping cells evenly spread out and healthy, the Company’s creation helps increase production yields, improve quality, and reduce waste, without slowing growth. With this innovation, CellRev directly tackled one of the biggest challenges in scaling up cell-based production, helping to cut costs and make large-scale manufacturing more viable. The technology has been proven across a range of widely used cell types, including those used in vaccines, regenerative medicine, and other advanced therapies, with some processes seeing productivity increases of up to three times.
In addition to its enzyme-based portfolio, CellRev’s R&D pipeline targeted broader applications in continuous cell culture systems, integrating its aggregation control technology with micro-carrier platforms from major suppliers such as Sartorius and Kuraray. The Company’s work has been showcased at leading sector conferences, including Advanced Therapies 2025, reflecting its role as an innovator within the biotech space. CellRev served a global customer base of biopharma, vaccine producers, regenerative medicine developers, and cultivated meat companies. The Company’s commercial model centred on supplying high-value media additives in trial and production volumes, supported by technical expertise, case studies, and collaborative development projects.
With a strong scientific foundation, validated commercial traction, and an industry-relevant IP portfolio encompassing patent applications, proprietary formulations, and trade secrets, acquiring the CellRev assets offers a rare opportunity for strategic acquirers seeking to integrate high-impact process optimisation technology into their bio-manufacturing operations.
The CellRev brand has quickly established itself as a recognised innovator in advanced cell manufacturing. Built around a mission to solve some of the biggest bottlenecks in scaling adherent cell culture, the brand has earned a reputation for delivering scientifically robust and commercially relevant solutions to the biopharmaceutical, regenerative medicine, and cultivated meat sectors.
Through validation studies, high-profile conference appearances, and collaborations with leading industry partners, CellRev has positioned itself as a trusted name for organisations seeking to improve yields, reduce costs, and accelerate commercialisation in cell-based production.
Acquiring the CellRev brand offers potential acquirers a platform for expansion into diverse end markets, backed by the credibility and recognition the brand has built within the industry.
The AggreGuard and Continuase brands represent CellRev’s core product brands. Both have been developed to address critical bottlenecks in large-scale adherent cell culture, with applications spanning biopharmaceutical, regenerative medicine, vaccines, and cultivated meat.
AggreGuard is a proprietary process additive designed to prevent cell aggregation during culture, helping to maintain cell health, improve uniformity, and increase production yields without slowing growth. The brand and products have been successfully validated across multiple industry-standard cell lines, demonstrating significant productivity gains and scalability benefits.
Continuase is CellRev’s next-generation continuous cell manufacturing enzyme solution, engineered to support uninterrupted culture processes while maintaining high cell viability and performance. By enabling extended production runs and reducing downtime, Continuase offers the potential for step-change improvements in efficiency and cost-effectiveness for large-scale manufacturing.
Together, the product brands embody CellRev’s commitment to practical, results-driven innovation. Backed by robust proof-of-performance data, they provide a strong foundation for any acquirer seeking to expand into process optimisation technologies for the life sciences and cell-based production markets.
The Company holds rights in UK-registered trade marks protecting the “AggreGuard” and “Continuase” product brand names.
The Company likely holds unregistered rights associated with the “CellRev” brand name and logos.
Full details on the Company’s trade marks are available via a virtual data room.
CellRev’s patent applications bring together three international patent families and a comprehensive body of proprietary technical know-how, creating a defensible platform for continuous adherent cell manufacturing.
The patent applications, covering a novel continuous bioprocessing platform, enzyme-based methods for continuous cell detachment, and culture techniques to prevent aggregation in major markets including the UK, US, Europe, China, India, and Japan. The Company’s filings target core industry pain points of cost, scalability, and yield, making them directly applicable to biopharmaceutical, regenerative medicine, and cultivated meat production.
Supporting the patents is a depth of process know-how built over years of R&D and validation, including mastery of culturing diverse cell types, running multiple culture formats from flasks to bioreactors, developing and scaling advanced bioprocesses, micro-carrier manufacturing, continuous harvest techniques, and precision enzyme modelling. The Company’s documented know-how also spans viral titre modelling, preparation of specialist coatings, and early-stage innovations in media waste removal and rejuvenation.
The Company’s combination of patent applications and proven know-how offers an acquirer immediate access to fully developed technology with broad application potential and a clear route to commercial scale.
The Company holds the primary cellrev.co.uk domain name, along with the cellrev.com and cellularevolution.co.uk domain names.
The Company likely holds the copyright in the website content hosted at its domains, which present its technologies and their commercial applications.
Rights in social media accounts are also available to acquire across LinkedIn and Instagram.
Full details on the Company’s social media accounts are available via a virtual data room.
A separate auction is being conducted for CellRev’s tangible assets, which include a range of specialist laboratory and office equipment. Key items comprise equipment like Nucleocounter, Cytation, UFMini centrifuge and all other centrifuges, Applikon bioreactors and microscopes/incubators. These assets are well-suited to micro-carrier-based culture, continuous processing trials, and viral vector production workflows.
For further information on the tangible asset auction, please contact the Hilco representatives mentioned below.
Hilco is acting as exclusive agent to the Company and its Joint Administrators in connection with the proposed sale of some or all of the Company’s assets. The Joint Administrators acts as an agent of the Company and without personal liability.
All sales are made strictly on an “as is, where is” basis. Only such right, title and interest (if any) as the Company may have in the assets will be transferred to a purchaser. No warranties, guarantees, or representations (express or implied) are provided by the Company, its Joint Administrators, or Hilco in respect of the assets or any information supplied. All parties must rely on their own enquiries and due diligence. Any information provided is for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 10% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of sale.
Legal completion must occur within five (5) business days of offer acceptance, unless otherwise agreed in writing by the Company and its Joint Administrators.
